Navigation Links
Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in a Phase 1/2 clinical trial of Glyceryl Tri (4-Phenylbutyrate) (GT4P) in patients with urea cycle disorders (UCDs).


"UCDs are complex disorders which require a multi-faceted management approach, including a protein restricted diet, amino acid supplementation, and pharmacological therapy," said Brendan Lee, M.D., Ph.D. the first investigator to enroll a patient in the GT4P Phase 1/2 trial and Professor, Department of Molecular and Human Genetics at Baylor College of Medicine. "We look forward to seeing the results from the clinical trials of GT4P in the management of UCDs."

The phase 1/2 study is designed to evaluate the safety, tolerability and ammonia scavenging effects of GT4P compared to BUPHENYL(R) (sodium phenylbutyrate) in patients with UCDs. A total of up to ten adults with stable UCD will be included in the trial, which is being conducted at US-based clinical sites. Estimated duration of treatment is 3 to 4 weeks.

"We are very excited about our research of GT4P focused on the chronic management of urea cycle disorders," said Marvin Garovoy, Senior Vice President of Clinical Development of Hyperion Therapeutics, Inc. "Initiation of this trial marks the beginning of several Hyperion clinical programs aimed at developing new therapies for hepatic disease."

About GT4P

GT4P is composed of a glycerol backbone covalently attached via ester linkages to three molecules of phenylbutyrate. It is a prodrug of BUPHENYL(R) (a currently FDA-approved adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS)), and a pre-prodrug of phenylacetate (PAA).

About Urea Cycle Disorder

A urea cycle disorder is an inherited, inborn error of metabolism present in an estimated 1 in 10,000 live births in the U.S. Patients with UCDs lack or are deficient in one of the key enzymes that comprise the urea cycle, the body's primary vehicle for removing ammonia, a potent neurotoxin, from the bloodstream. The age of onset of UCDs is typically in the neonatal period, but onset can occur at any age, depending on the severity of the disorder. Left untreated, UCDs can cause dangerously heightened levels of ammonia in the bloodstream (hyperammonemia) resulting in brain damage, coma, and/or death.

There is no cure for UCDs. Adherence to a low-protein diet is a key component to chronic disease management. Current therapies include arginine supplementation, which drives functional parts of the urea cycle, essential amino acid supplementation, replacement of urea cycle intermediates, and administration of nitrogen-scavenging drugs including BUPHENYL(R) for chronic management and AMMONUL(R) (sodium phenylacetate and sodium benzoate) disease Injection 10%/10% for episodes of acute hyperammonemia. Orthotopic liver transplantation may also be considered for patients with severe disease.

About Hyperion Therapeutics

Hyperion Therapeutics is a specialty therapeutics company focused on becoming a global leader in gastrointestinal (GI) and hepatology therapeutic programs and products that address underserved patient populations or unmet medical needs. The company has assembled a seasoned executive team with extensive industry experience developing and commercializing specialty pharmaceutical products. Hyperion is headquartered in South San Francisco, CA. For additional information, visit:


AMMONUL(R) is indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. The most common adverse reactions are vomiting (9%), hypokalemia (7%), hyperglycemia (7%), convulsions (6%), and mental impairments (6%). Do not administer to patients with known hypersensitivity to sodium phenylacetate or sodium benzoate. Acute symptomatic hyperammonemia should be treated as life-threatening. Uncontrolled hyperammonemia can result in brain damage or death. Dialysis may be required, preferably hemodialysis, to remove a large burden of ammonia. Administration must be through a central line; use of a peripheral line may cause burns. Do not administer undiluted product. Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses should not be administered. Use caution when administering to patients with hepatic or renal insufficiency. AMMONUL(R) may cause nausea and vomiting. An antiemetic may be administered during infusion. See the prescribing information for a complete listing of warnings, precautions, and drug interactions.


BUPHENYL(R) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). BUPHENYL(R) should not be administered to patients with known hypersensitivity to sodium phenylbutyrate or any component of this preparation. The most common adverse reactions associated with BUPHENYL(R) were amenorrhea dysfunction, decreased appetite, body odor (probably caused by its metabolite phenylacetate) and bad taste or taste aversion. Patients with urea cycle disorders should not take valproic acid, haloperidol, or steroids as these drugs have been reported to increase blood ammonia levels, and probenecid may affect the kidneys' excretion. Use with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states where there is sodium retention with edema. Use caution when administering to patients with hepatic or renal insufficiency or inborn errors of beta oxidation. The safety or efficacy of doses in excess of 20 grams (40 tablets) per day has not been established.

AMMONUL(R) and BUPHENYL(R) are registered trademarks of Ucyclyd Pharma, Inc.

Full Prescribing Information for AMMONUL(R) and BUPHENYL(R) are available at and, respectively, or by contacting Hyperion Therapeutics, Inc.

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, ... acquiring and developing innovative therapies for ear, nose, and ... Keith A. Katkin as chairman of the company,s ... chief executive officer for OticPharma, Ltd.  "Keith brings a ... he will be able to share this experience and ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New ... is so important to this key industry segment, Regis Technologies has decided to sponsor ... December 4th at 11am EST. , Federal law does not allow new drugs to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
(Date:11/30/2015)... ... , ... GKhair & Tibolli team members and artists were excited and proud ... 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. The ... of the line fashion journalists. The San Juan Beauty Show carries immense credibility among ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... for healthcare professionals worldwide today released the results of a survey of educational ... East and Africa found a growing global demand for high quality online and ...
Breaking Medicine News(10 mins):